By Fineline Cube 
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK) branded drug Flonase and represents China’s first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).
Product and Market Context
Fluticasone propionate, a synthetic glucocorticoid, is indicated for the treatment of nasal congestion related to allergic rhinitis. In China’s nasal corticosteroid spray market, which reached RMB 3.54 billion (USD 486 million) in 2023, the three dominant products—mometasone, budesonide, and fluticasone—collectively captured a 65% market share, equivalent to RMB 2.3 billion (USD 315 million). Grand Pharmaceutical’s entry into this market underscores its commitment to providing accessible and effective treatment options for patients with allergic rhinitis.-Fineline Info & Tech